Higher Dose of This Antibiotic Can Help In Tuberculosis Recovery: Study
A higher dose of rifampicin -- a bactericidal antibiotic used primarily to treat tuberculosis (TB) -- may be safe, and its use can potentially lead to recurrence-free survival in patients with pulmonary TB, according to a recent study by the Indian Council of Medical Research (ICMR).
TB is curable but still remains the most common cause of death due to infectious diseases, with an estimated 1.3 million deaths globally in 2022. Rifamycins are a crucial drug group in the anti-TB regimen, which sterilise the lesions and aid in recurrence-free cure.
Currently, rifampicin is administered at 10 mg/kg for six months to all patients with pulmonary TB.
The team reviewed the available evidence from published clinical trials to determine whether higher doses of rifampicin (more than 15 mg/kg) are more efficacious and safer.
"Compared to standard dose, higher doses of rifampicin were found to lead to early sputum conversion in eight weeks and thus faster TB bacteria clearance," said corresponding author Dr Leeberk Raja Inbaraj, Department of Clinical Research, ICMR- National Institute for Research in Tuberculosis, Chennai.
Early sputum conversion is a valuable tool widely used as a surrogate marker for treatment response and those who are at risk for relapse in pulmonary TB.
"The ability of high-dose rifampicin to achieve early sputum conversion and eliminate the persistent bacteria that cause relapse could potentially lead to recurrence-free survival. Early bacterial clearance is also of public health importance as this could potentially reduce disease transmission in the community," the researchers said.
Notably, the study showed 20-30mg/kg rifampicin as the best balance.
"This dose range showed better sputum conversion without a significant increase in serious side effects and may be considered in TB treatment," revealed the study, published in the Indian Journal of Medical Research (IJMR).
On the other hand, doses above 30 mg/kg, although beneficial, came with severe side effects such as serious liver damage (hepatotoxicity) and adverse drug reactions (ADR), leading to treatment discontinuation.
The study showed no reduction in death or treatment failure in people with more than 15 mg/kg doses of rifampicin.
"High doses did not reduce mortality or treatment failure at 6 months compared to standard treatment," the team said.
"This dose could be administered with close monitoring of adverse events and hepatotoxicity. There is an urgent need for adequately powered trials that assess long-term treatment outcomes, including recurrence," they added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
4,106 panchayats TB-free, CG wins nat'l award for campaign success
Raipur: Chhattisgarh is making rapid strides towards tuberculosis (TB) elimination with declaration of 4,106 gram panchayats TB-free. Chhattisgarh also received a national award for excellent implementation of the TB-Free Gram Panchayat programme. The state is implementing a comprehensive action plan to achieve PM Narendra Modi's goal of making India TB-free by 2025. The "Nikshay-Niramay Chhattisgarh – 100-day campaign" began on Dec 7, 2024. The campaign aimed to combat TB at the grassroots level. Under the initiative, authorities identified and listed high-risk individuals through door-to-door surveys across all districts. They conducted tests using modern techniques. Public participation played a significant role in the campaign's success. The Governor, CM, and Health minister adopted TB patients and provided nutritional support as 'Nikshay Mitras'. Over 15,000 new Nikshay Mitras have registered and provided nutritional assistance to more than 34,000 patients. Chief minister Vishnu Deo Sai directed authorities to focus on vulnerable sections of society often deprived of healthcare services. These include prisoners, elderly residents in old age homes, students in hostels, and factory workers. Sai stated that when govt commitment and public cooperation unite, change transforms from a goal into an achievement. Chhattisgarh is becoming a living example of this.
Time of India
2 hours ago
- Time of India
Sion hosp to start TB containment lab to test for drug-resistant cases
Mumbai: After years of relying on external partnerships, Sion hospital is set to expand its efforts to hunt for drug-resistant tuberculosis by adding a 'TB containment' laboratory. It will allow the hospital to conduct drug sensitivity tests on 5%-10% of positive TB cases of 15,000 tested there annually. Previously, all positive samples were sent to private labs registered under National Tuberculosis Elimination Programme, like PD Hinduja Hospital or, more recently, Thyrocare, for testing of drug-resistant strains. A tender for the containment lab, which will allow safe testing of samples, was floated earlier this month. Sion hospital dean Dr Mohan Joshi said once the tender process is completed, it should take a few months for the lab to become functional. The city reports about 50,000 to 60,000 new TB cases annually, of which a few thousand are drug-resistant cases. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai Dr Dilip Turbadkar, head of microbiology dept said each year, between 1% and 2% of total positive TB samples found at Sion hospital are drug-resistant cases. Another microbiologist at the hospital said: "In-house testing tools will improve turnaround time for diagnosis. It's quicker and more convenient." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Back Pain Treatments That Might Surprise You! Back Pain Treatment | Search Ads Undo The new lab will use Mycobacteria Growth Indicator Tube system that relies on liquid culture methods to detect TB bacteria and assess drug-resistance. The technique delivers results in 7-21 days, depending on bacterial load, which is faster than traditional solid culture methods that can take up to 8 weeks. However, liquid cultures come with higher bio-safety risks. "So far, we've worked with solid cultures in the hospital, which are safer...," the microbiologist said. To minimise this risk, the containment lab will have a filtration system equipped with ventilation to allow air to flow inward, not outward. Dr Turbadkar said similar containment labs exist at KEM and JJ hospitals. For any such lab, permissions are needed from the central TB division, which then provides technical staff.
Time of India
4 hours ago
- Time of India
Infrastructure gaps pose hurdles for Palamu's TB elimination goals
1 2 Daltonganj: The Palamu district TB department is facing challenges in conducting Cy-Tb skin test and IGRA test that are done on people to diagnose TB. Cy-Tb skin test, an advanced version of the Montoux TB test, helps detect latent TB infection. Similarly, IGRA test serves to identify dormant TB. Former civil surgeon Dr Anil Kumar Sriwastav said, "State govt TB doctors and community health officers conduct Cy-Tb skin tests, while an NGO handles IGRA tests. X-ray screening of patients is mandatory before both tests to rule out any patch of TB in a person. Person having any patch of TB is not to be put to either of these tests." The absence of X-ray facilities at the Medinirai Medical College and Hospital, Daltonganj, has hindered testing. X-ray services are available at Panki and Harihurganj community health centres and the Chhaterpur sub-divisional hospital. The district also faces infrastructure challenges, including limited availability of Tru Nat machines, CB Nat machines, and microscope centres. Respiratory health risks are high for the over 21 lakh residents of the district which has many stone crushing plants. Palamu has 4,000 active TB cases. The department aims to test 3,000 additional individuals for latent TB using CyTb, whilst another 3,000 will undergo IGRA testing. "We are committed to eliminate TB from the district despite challenges," he added.
